Previous 10 | Next 10 |
Do you, or did you, own shares of Exscientia plc (NASDAQ:EXAI)? Did you purchase your shares between March 23, 2022 and February 12, 2024, inclusive? Did you lose money in your investment in Exscientia plc? Do you want to discuss your rights? NEW YORK, NY / ACCESSWIRE / May 1, ...
NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased securities of Exscientia plc (“E...
Do you, or did you, own shares of Exscientia plc (NASDAQ:EXAI)? Did you purchase your shares between March 23, 2022 and February 12, 2024, inclusive? Did you lose money in your investment in Exscientia plc? Do you want to discuss your rights? NEW YORK, NY / ACCESSWIRE / April 30, 202...
2024-04-24 17:41:05 ET Gainers: Acrivon Therapeutics ( ACRV ) +19% . Impinj ( PI ) +10% . Exscientia ( EXAI ) +6% . Churchill Downs ( CHDN ) +5% . PowerFleet ( PWFL ) +5% . Losers: Meta Platforms ( META ) ...
2024-04-24 09:19:50 ET More on Moderna Moderna Investors Should Beware Patent-Dispute Fallout Moderna: Considering The Cancer Vaccine Angle Moderna Continues To Build A Pipeline S&P 500 stocks with biggest estimated EPS declines for Q1 Moderna sto...
2024-03-27 01:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-21 16:22:02 ET More on Exscientia Exscientia plc (EXAI) Q4 2023 Earnings Call Transcript Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with a...
2024-03-21 11:53:17 ET More on S&P 500 Index: Chairman Powell Hits A Grand Slam Home Run Despite What The Fed Says, The Policy Is Still 'Higher-For-Longer' The Fed Is More Dovish Than The Market Anticipates 32 “Breakthroughs” stocks by BofA ...
2024-03-21 11:39:10 ET Exscientia plc (EXAI) Q4 2023 Results Conference Call March 21, 2024 8:30 AM ET Company Participants Chinedu Okeke - Associate Director-Strategy, IR Dave Hallett - Interim CEO, Chief Scientific Officer Ben Taylor - CFO, Chief Strategy Offic...
2024-03-21 11:12:18 ET More on Exscientia Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade) Exscientia FY 2023 Earnings Preview Anagenex expands leadership team with appointment of Adrian Schreyer as CTO Seeking Alpha ...
News, Short Squeeze, Breakout and More Instantly...
Maximises upside potential of precision-designed GTAEXS617 with purchase of rights from GT Apeiron Monotherapy dose escalation data readout for ELUCIDATE Phase 1/2 trial on track for second half of 2024 Combination dose escalation study starting with HR+/HER2- breast cancer to com...
— State-of-the-art platform, built using Amazon Web Services technologies, integrates generative AI drug design and robotic lab automation to further accelerate Exscientia’s ability to deliver high quality drug candidates at faster speed and lower cost — Exscientia ...